Amanote Research
Register
Sign In
Systemic Administration of siRNA With Anti-Hb-Egf Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer
doi 10.1021/acs.molpharmaceut.7b01055.s001
Full Text
Open PDF
Abstract
Available in
full text
Date
Unknown
Authors
Unknown
Publisher
American Chemical Society (ACS)
Related search
Layer-By-Layer Nanoparticles for Systemic Codelivery of an Anticancer Drug and siRNA for Potential Triple-Negative Breast Cancer Treatment
ACS Nano
Materials Science
Nanoscience
Engineering
Nanotechnology
Astronomy
Physics
Cetuximab-Conjugates Nanoparticles for the Treatment of Triple Negative Breast Cancer
Silencing the Roadblocks to Effective Triple-Negative Breast Cancer Treatments by siRNA Nanoparticles
Endocrine-Related Cancer
Cancer Research
Endocrinology
Oncology
Metabolism
Diabetes
Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple Negative Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
Targeting MYC for Triple-Negative Breast Cancer Treatment
Oncoscience
Cancer Research
Oncology
Repositioning of Anti-Parasitic Drugs in Cyclodextrin Inclusion Complexes for Treatment of Triple-Negative Breast Cancer
AAPS PharmSciTech
Evolution
Ecology
Systematics
Crop Science
Aquatic Science
Behavior
Pharmaceutical Science
Medicine
Agronomy
Drug Discovery
Targeted Nanoparticles for Image-Guided Treatment of Triple-Negative Breast Cancer: Clinical Significance and Technological Advances
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
Medicine
Bioengineering
Nanotechnology
Biomedical Engineering
Nanoscience
Aminoflavone-Loaded EGFR-targeted Unimolecular Micelle Nanoparticles Exhibit Anti-Cancer Effects in Triple Negative Breast Cancer
Biomaterials
Mechanics of Materials
Biophysics
Biomaterials
Bioengineering
Composites
Nanoscience
Nanotechnology
Ceramics
Triple-Negative Breast Cancer
